113 related articles for article (PubMed ID: 29484999)
1. The Immunomodulatory Role of G2013 (α-L-Guluronic Acid) on the Expression of TLR2 and TLR4 in HT29 cell line.
Farhang H; Sharifi L; Dallal MMS; Moshiri M; Norouzbabaie Z; Bokaie S; Aletaha S; Zargar SJ; Mirshafiey A
Curr Drug Discov Technol; 2019; 16(1):91-95. PubMed ID: 29484999
[TBL] [Abstract][Full Text] [Related]
2. Antagonistic Property of G2013 (α-L-Guluronic Acid) on Gene Expression of MyD88, Tollip, and NF-κB in HEK293 TLR2 and HEK293 TLR4.
Sharifi L; Aghamohammadi A; Aletaha S; Bigdeli R; Asgary V; Bokaie S; Asgardoon MH; Azizi G; Mirshafiey A
Endocr Metab Immune Disord Drug Targets; 2019; 19(2):144-149. PubMed ID: 30784390
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory Effect of G2013 (α-L-Guluronic Acid) on the TLR2 and TLR4 in Human Mononuclear Cells.
Sharifi L; Mohsenzadegan M; Aghamohammadi A; Rezaei N; Zavareh FT; Bokaie S; Moshiri M; Aghazadeh Z; Norouzbabaie Z; Azizi G; Mirshafiey A
Curr Drug Discov Technol; 2018; 15(2):123-131. PubMed ID: 28578651
[TBL] [Abstract][Full Text] [Related]
4. The Inhibitory Role of M2000 (β-D-Mannuronic Acid) on Expression of Toll-like Receptor 2 and 4 in HT29 Cell Line.
Sharifi L; Moshiri M; Dallal MMS; Asgardoon MH; Nourizadeh M; Bokaie S; Mirshafiey A
Recent Pat Inflamm Allergy Drug Discov; 2019; 13(1):57-65. PubMed ID: 30539708
[TBL] [Abstract][Full Text] [Related]
5. Effects of guluronic acid (G2013) on gene expression of TLR2, TLR4, MyD88, TNF-α and CD52 in multiple sclerosis under in vitro conditions.
Noorbakhsh SM; Razavi A; Moghadam NB; Saadat P; Hoseini M; Aghazadeh Z; Mobini M; Oraei M; Mirshafiey A
Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):586-590. PubMed ID: 31594427
[No Abstract] [Full Text] [Related]
6. Effects of guluronic acid (G2013) on SHIP1, SOCS1 induction and related molecules in TLR4 signaling pathway.
Mortazavi-Jahromi SS; Farazmand A; Motamed N; Navabi SS; Mirshafiey A
Int Immunopharmacol; 2018 Feb; 55():323-329. PubMed ID: 29310108
[TBL] [Abstract][Full Text] [Related]
7. G2013 modulates TLR4 signaling pathway in IRAK-1 and TARF-6 dependent and miR-146a independent manner.
Hajivalili M; Pourgholi F; Majidi J; Aghebati-Maleki L; Movassaghpour AA; Samadi Kafil H; Mirshafiey A; Yousefi M
Cell Mol Biol (Noisy-le-grand); 2016 Apr; 62(4):1-5. PubMed ID: 27188726
[TBL] [Abstract][Full Text] [Related]
8. The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under
Tahmasebi S; Neishaboori H; Jafari D; Faghihzadeh E; Esmaeilzadeh A; Mirshafiey A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):562-570. PubMed ID: 34314306
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property.
Mirshafiey A; Mortazavi-Jahromi SS; Taeb M; Cuzzocrea S; Esposito E
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):162-168. PubMed ID: 29879894
[TBL] [Abstract][Full Text] [Related]
10. The Evaluation of Safety Property and Apoptotic Efficacy of α-L-Guluronic Acid (G2013), as a Novel NSAID, Under
Hassani S; Afshari JT; Jafarnezhad-Ansariha F; Mirshafiey A
Recent Adv Inflamm Allergy Drug Discov; 2022; 15(1):9-15. PubMed ID: 34503439
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of G2013 (α-L-guluronic acid) efficacy on PC-3 cells through inhibiting the expression of inflammatory factors.
Bagherian Z; Mirshafiey A; Mohsenzadegan M; Farajollahi MM
Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):254-263. PubMed ID: 34699087
[TBL] [Abstract][Full Text] [Related]
12. Effect of Guluronic Acid (G2013), As a New Anti-inflammatory Drug on Gene Expression of Pro-inflammatory and Anti-inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients.
Bakhtiari T; Azarian S; Ghaderi A; Ahmadzadeh A; Mirshafiey A
Iran J Allergy Asthma Immunol; 2019 Nov; 18(6):639-648. PubMed ID: 32245307
[TBL] [Abstract][Full Text] [Related]
13. M2000 (β-D-Mannuronic Acid) as a Novel Antagonist for Blocking the TLR2 and TLR4 Downstream Signalling Pathway.
Aletaha S; Haddad L; Roozbehkia M; Bigdeli R; Asgary V; Mahmoudi M; Mirshafiey A
Scand J Immunol; 2017 Feb; 85(2):122-129. PubMed ID: 27943385
[TBL] [Abstract][Full Text] [Related]
14. Effects of guluronic acid, as a new NSAID with immunomodulatory properties on IL-17, RORγt, IL-4 and GATA-3 gene expression in rheumatoid arthritis patients.
Khadem Azarian S; Jafarnezhad-Ansariha F; Nazeri S; Azizi G; Aghazadeh Z; Hosseinzadeh E; Mirshafiey A
Immunopharmacol Immunotoxicol; 2020 Feb; 42(1):22-27. PubMed ID: 31856612
[No Abstract] [Full Text] [Related]
15. The role of Toll-like receptor 4 in high-glucose-induced inflammatory and fibrosis markers in human peritoneal mesothelial cells.
Choi SY; Ryu HM; Choi JY; Cho JH; Kim CD; Kim YL; Park SH
Int Urol Nephrol; 2017 Jan; 49(1):171-181. PubMed ID: 27722989
[TBL] [Abstract][Full Text] [Related]
16. Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties.
Mortazavi-Jahromi SS; Nazeri S; Jafarnezhad-Ansariha F; Oraei M; Mirshafiey A
Immunol Res; 2019 Feb; 67(1):108-115. PubMed ID: 30474833
[TBL] [Abstract][Full Text] [Related]
17. The expression of Toll-like receptors in patients with acute myeloid leukemia treated with induction chemotherapy.
Rybka J; Butrym A; Wróbel T; Jaźwiec B; Stefanko E; Dobrzyńska O; Poręba R; Kuliczkowski K
Leuk Res; 2015 Mar; 39(3):318-22. PubMed ID: 25624047
[TBL] [Abstract][Full Text] [Related]
18. Expression of Toll-like Receptor 2 and Toll-like Receptor 4 in Tuberculous Pleural Effusion.
Lin Y; Feng T; Lan J; Chen C; Qin Z; Wu Y; Shi H; Ye J; Wei C; Wang W; Huang L
Med Chem; 2017; 13(6):569-576. PubMed ID: 28494727
[TBL] [Abstract][Full Text] [Related]
19. Pivotal cytokines and their transcription factors are the targets of guluronic acid (G2013) for inhibiting the immunopathogenesis process of multiple sclerosis.
Hossein-Khannazer N; Shabani S; Farokhfar M; Azizi G; Asarzadegan F; Safarpour Lima B; Mirshafeiey A
Drug Dev Res; 2020 Jun; 81(4):511-516. PubMed ID: 32103523
[TBL] [Abstract][Full Text] [Related]
20. TLR2 and TLR4 polymorphisms influence mRNA and protein expression in colorectal cancer.
Proença MA; de Oliveira JG; Cadamuro AC; Succi M; Netinho JG; Goloni-Bertolo EM; Pavarino ÉC; Silva AE
World J Gastroenterol; 2015 Jul; 21(25):7730-41. PubMed ID: 26167073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
